key: cord-0740864-5g39q1vq
authors: Wiriyachaiporn, Natpapas; Sirikaew, Siriwan; Chitchai, Nawakarn; Janchompoo, Pareena; Maneeprakorn, Weerakanya; Bamrungsap, Suwussa; Pasomsub, Ekawat; Japrung, Deanpen
title: Pre-clinically evaluated visual lateral flow platform using influenza A and B nucleoprotein as a model and its potential applications
date: 2021-05-24
journal: RSC advances
DOI: 10.1039/d1ra01361k
sha: c8e5cc1af9a1f7179a3edb3942a6faab4954778c
doc_id: 740864
cord_uid: 5g39q1vq

A visual colorimetric rapid screening system based on a lateral flow device for simultaneous detection and differentiation between influenza A and B nucleoprotein as a model was developed. Monoclonal antibodies, specific for either influenza A or B nucleoproteins, were evaluated for their reactivities and were used as targeting ligands. With the best antibody pairs selected, the system exhibited good specificity to both viruses without cross reactivity to other closely related respiratory viruses. Further semi-quantitative analysis using a strip reader revealed that the system is capable of detecting influenza A and B protein content as low as 0.04 and 1 ng per test, respectively, using a sample volume as low as 100 μL, within 10 minutes (R(2) = 0.9652 and 0.9718). With a performance comparison to the commercial tests, the system demonstrated a four-to-eight-fold higher sensitivity. Pre-clinical evaluation with 101 nasopharyngeal swabs reveals correlated results with a standard molecular approach, with 89% and 83% sensitivity towards influenza A and B viruses, and 100% specificity for both viruses.

The recent coronavirus outbreak has brought to our attention the impact of acute respiratory tract infections. Of these respiratory pathogens, inuenza remains one of the most highly contagious respiratory illnesses, affecting people of all ages worldwide. Despite being distinguished by seasonal epidemics, affecting 5-15% of the world population, occasional pandemic outbreaks usually take place every 10-15 years. This is due to the emergence of new strains caused by mutation of the strains circulating in the community. 1 It was reported that at least 3-5 million people have severe illnesses with complications and need further hospitalization, whilst there are approximately 250 000-500 000 deaths from inuenza annually. 2 This raises an awareness of economical and health burdens caused by both epidemic and pandemic inuenza outbreaks. In order to apply a preventive and effective treatment strategy, early diagnosis is urgently needed. 3 Clinical diagnosis of respiratory illnesses based on clinical symptoms alone can be limited due to the overlapping symptoms of inuenza-like illness (ILI) caused by different viral pathogens, including respiratory syncytial virus (RSV), rhinovirus, adenovirus, coronavirus, metapneumovirus, bocavirus, enterovirus, and parainuenza virus. 3, 4 To screen and diagnose patients with inuenza virus infection, a number of different laboratory techniques, including conventional viral culture approach, molecular assays, serological method, immunouorescence staining, and rapid antigen diagnostic tests, have been used. [5] [6] [7] Whilst viral culture and molecular assays provide the information regarding the identication of the outbreak strain and subtypes, serological method and immunouorescence staining technique are useful for a detection and identication of antibodies to seasonal inuenza viruses and the specic isolates. Although these techniques provide useful information, they are time-consuming techniques and their usefulness as a screening test oen limited by the sophisticated step, expensive equipment, laboratory facilities, and expertise of the trained personnel. 8 To overcome these limitations, rapid testing can be more useful as a screening tool to prevent the seasonal episodes, control the outbreaks, and prepare for the next pandemic.

Of those technologies developed for a rapid pathogen detection i.e. isothermal nucleic acid amplication, micro-uidic, three-dimensional nanostructured substrates, and mobile handheld technologies, [9] [10] [11] [12] [13] and lateral ow immunoassay, the latter technique has been used increasingly as POC and point-of-need applications, 14 especially in low-resource settings where laboratory facilities are limited. 15, 16 These include the tests on biomarkers, 17 infectious agents, 18 and toxic compounds. [19] [20] [21] The main advantage of lateral ow technique is its simplicity, rapidity, and inexpensiveness. Within the system, different labels have been employed to facilitate the detection; 22 for example, including uorescent-based system using uorescent dyes/nanoparticles, 23 SERS-based system using anisotropic metal nanoparticles, 24 signal amplication-based system using enzyme as labels. 25 However, these systems have limitations in requiring additional steps and instruments, restraining their POC applications. 26 To achieve rapid screening purposes, simple system using gold nanoparticles (GNP) as labels has been extensively used for direct visual detection. 27, 28 Previously, rapid testing for screening respiratory pathogens, including inuenza viruses, have been widely used. Differences in diagnostic sensitivity and specicity can be observed in difference assays. For example, Han et al., reported the pooled sensitivity and specicity of 0.84 and 0.97, respectively, for such tests based on lateral ow immunoassay technique. 29 On the other hand, the tests can be valuable alternative method for a rapid screening due to its ease-of-use, rapidity, and applicability in POC applications. The test; therefore, can be helpful for diagnostic and treatment decision in clinical settings. [30] [31] [32] Here, a visual colorimetric rapid screening system, based on lateral ow device for a simultaneous detection and differentiation between inuenza A and B viruses as a model, was developed. To target the virus, inuenza A and B nucleoproteins were selected as the target protein molecules. Of those inuenza proteins, nucleoprotein is recognized as one of the most conserved proteins in the virus virion. 33, 34 Using an in-house treatment and assembly of lateral ow strip test, the selection of targeting ligands, and the use of GNP as reporters, the system provides a ready-to-use platform for a direct visualization within 10 minutes, without the need of extra resources. The performance of the system is evaluated for its sensitivity and speci-city, compared to that obtained from the available commercial tests. Subsequently, the system is pre-clinically evaluated with clinical specimens, correlated to molecular approach, to assess its application as an inuenza screening tool. With the use of lateral ow device for detecting multiple targets, the system can be developed and applied as a rapid screening tool for respiratory illnesses caused by other pathogens.

Monoclonal antibody (mAb) to inuenza A virus activity. To evaluate the activity of the mAbs in binding to their target protein, mAbs specic to inuenza A and B viruses were assessed for their reactivity using sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and western blotting analyses. Proteins, including inuenza A virus nucleoprotein, inuenza B, RSV, adenovirus, and parainuenza virus proteins, were loaded on the gel. Aer staining and destaining process, a clear distinct band at approximately 56 kDa and a band at 53 kDa, but with a lesser intensity, were observed in the lane loaded with inuenza A nucleoprotein (Fig. S1A , lane 1, ESI †). Western blotting analysis revealed the presence of the bands at 56 and 53 kDa, without cross reactivity to other virus proteins (Fig. S1B , lane 1, ESI †). This result indicates that the mAb is specic to inuenza A nucleoprotein. The size of the protein at 56 kDa was shown to be correlated to the size of monomeric nucleoprotein. Whilst the size of monomeric inuenza A nucleoprotein was reported to be 56 kDa, the truncated fragment at approximately 53 kDa as a result of proteolytic degradation of extracellular nucleoprotein has also been described earlier. [33] [34] [35] mAb to inuenza B virus activity. Similarly, mAb to inuenza B virus was also evaluated in the same manner. SDS-PAGE analysis showed that there was a clear protein band present at 64 kDa, while other proteins having the size below 64 kDa can also be observed, although in a lesser extent (Fig. S1C , lane 1, ESI †). It should be noted that inuenza B virus antigen was derived from inactivated Madin-Darby canine kidney (MDCK) cells infected with inuenza B virus. As a result, other proteins with other sizes than that of 64 kDa could also be observed. However, western blotting analysis has showed only the presence of the protein at 64 kDa, without cross reactivity to other proteins (Fig. S1D , lane 1, ESI †). The size of the protein observed in the analysis was found to be matched with that of inuenza B nucleoprotein at 64 kDa. 36 This result conrmed that the mAb reacted specically to inuenza B virus proteins, without cross reactivity to other virus proteins.

Schematic diagram depicted in Fig. 1a illustrated the application of the developed system for screening inuenza A and B antigens in one test. The components of the system, which consisted of sample application area, conjugate reservoir area, signal detection area, and absorbent pad was also illustrated in Fig. 1b . The principle integrates a specic recognition between the target antigen and the selected mAb pair, and a separation of the target molecules through the mean of chromatography. To enable a simple and direct visualization, GNP was used as reporter molecules. Within the device, a specic capture of inuenza A and B virus antigens was achieved simultaneously through antibody-antigen complexation. As a sample migrated along the device, the target proteins were recognized by the GNP-mAb conjugates functioned as the detector probe. The complexes were then owed and captured by the mAb immobilized on the test line (T-line) position of the reacting area. The excess conjugates were then owed along the device and captured by the secondary antibody on the control line (C-line) position. The presence of both T-line and C-line signal indicated a positive result, meanwhile the presence of the C-line only can be referred to as negative result.

Monodispersed spherical GNP were synthesized and obtained. Transmission electron microscopy (TEM) and dynamic light scattering (DLS) analysis were used to characterize the particles. Fig. 2 reveals TEM images of the particles, demonstrating that the particles before and aer conjugation to either mAb specic to inuenza A or B virus were homogenously dispersed. Using DLS analysis, it is also shown that the average hydrodynamic size of the plain particles was 24.0 AE 0.1 nm, whilst the size of particles aer conjugated to mAb specic to inuenza A and mAb specic to inuenza B were 34.6 AE 0.9 nm and 44.4 AE 2.3 nm, respectively. DLS data for the size distribution of GNP before and aer antibody conjugation were shown in Fig. S2 , ESI. † To further characterize the particles, the zeta potential of the particles was determined. While the plain particles displayed a negative zeta potential of À33.9 AE 0.4 mV, the particles aer conjugated to mAb specic to inuenza A and mAb specic to inuenza B exhibited À17.6 AE 0.6 mV and À20.1 AE 0.1 mV, respectively. The increased in the size and charge of the particles aer conjugation suggested that the conjugation was successful.

Subsequently, the particles were characterized for the change in absorption spectrum. Fig. S3 (ESI †) showed the maximum of the absorption peak (A max ) at 526 nm of the plain particles. Further, the particles showed A max at 532 and 534 nm aer conjugated to mAb specic to inuenza A and B, respectively. A small red-shi of the A max indicated the successful of the conjugation. In the presence of high salt concentration, the conjugated particles were observed to be stable, as shown by an unchanged in colour. In contrast, the particles without the conjugation were shown to be aggregated, resulting in a change in color and a shi in A max at 822 nm.

Determination of limit of detection. With a direct visualization method, it was revealed that the system was capable to detect and distinguish between inuenza A and B proteins, without cross reactivity to negative sample containing buffer only and other tested respiratory virus proteins When the inuenza A protein was used as a sample, the presence of the Fig. 1 Schematic diagram illustrated (a) the concept of the visual colorimetric rapid screening system based on lateral flow device for influenza A and B virus detection as a model. After sample collection, the sample was mixed with an analysis buffer before applied onto the device. The reaction was allowed to process, and the signal was visualized. The degree to which the formation of the complex at the test line position can be detected and quantified using the reader; (b) the components of the test system. Within the test, the virus proteins were recognized by the conjugates (GNP-mAb) and captured by the mAb on the test line position, enabling the detection signal. The presence of the control line indicates a validity of the test. Fig. 2 Characterization of the particles before and after mAb conjugation. TEM analysis revealed that the distribution of the particles before and after conjugation were monodispersed. The change in hydrodynamic size and charge of the particles after the conjugation was also confirmed using DLS analysis.

signal at the T-line position for inuenza A (TL1) can be observed correctly, without cross reactivity to T-line for inuenza B (TL2). Similarly, when inuenza B protein used as a sample, the signal at TL2 and C-line position were observed, without the signal at TL1 position. In all cases, the signal at the C-line position was presence.

Further attempt to determine the limit of detection (LOD) for inuenza A and B virus proteins was performed using inuenza A and B proteins prepared in a 2-fold serial dilution ranged from 0-300 ng per test for inuenza A protein and 0-8750 ng per test for inuenza B protein, respectively. Fig. 3a shows the signal visualization at TL1 against inuenza A protein concentration. Under optimal condition, it was showed that the TL1 signal decreased gradually when the protein was serially diluted until 0.04 ng per test (Fig. 3a) . Similarly, the signal visualization upon the addition of inuenza B proteins was also displayed with the limit of detection at 1 ng per test (Fig. 4a) . In the absence of the target protein, only C-line signal was detected in both cases. In contrast, a high concentration of the target protein caused the formation of the sandwich immunocomplex between mAbantigen, inducing the accumulation of GNP-mAb conjugates at the T-line. This subsequently enables direct signal visualization at the T-line position.

Subsequently to a direct visualization, semi-quantitative analysis using the reader was performed. Fig. 3b and 4b displayed the relationship between the target protein concentration and the relative signal response (RSR) for inuenza A and B proteins, respectively. The linear relationship in the range of 0-1.2 ng per test (R 2 ¼ 0.9652) for inuenza A protein is demonstrated (Fig. 3b, inset gure) . Similarly, the system also exhibited the linear relationship when the inuenza B protein was added in the range of 0-546 ng per test (R 2 ¼ 0.9718) (Fig. 4b,  inset gure) . The results showed that with a sample volume of 100 mL, the system was able to detect inuenza A and B proteins as low as 0.04 and 1 ng, respectively. Specicity of the system. To assess the specicity of the system, other closely related respiratory virus proteins including RSV, adenovirus, and parainuenza virus proteins, and other non-related proteins including avidin, c-reactive protein, hemoglobin, and insulin were included and used as a sample in the evaluation. Fig. 5 (inset gure) shows the signal visualization of the system containing inuenza A and B viruses, other virus proteins, and other tested proteins. A high signal response value was also demonstrated when both inuenza A and B protein antigens was added into the system (Fig. 5 ). In addition, in the system containing either inuenza A or B proteins, a high signal response was also observed. In contrast, in the absence of inuenza virus antigen (the negative control), no signal response was observed at both TL1 and TL2 position. It is also shown that other potentially related respiratory virus proteins and other non-related protein molecules showed no signal response at both T-line positions, suggesting that there was no signicant interference from these tested virus proteins and molecules. This suggests that the system showed a good specicity towards inuenza A and B viruses, without cross reactivity to the other tested virus proteins and molecules.

Comparison to the commercial tests. The performance of the system in detecting and differentiating inuenza A and B protein antigens was subsequently compared to those of the two commercial rapid tests, which is routinely used in inuenza screening. It was showed that the system was able to detect and distinguish between inuenza A and B protein antigens correctly, in the same manner as the commercial tests. However, it was demonstrated that the developed system can detect inuenza A protein antigen at 2-fold and 8-fold lower than that of commercial test 1 and 2, respectively, whilst the system is able to detect inuenza B protein antigen at the same concentration with both commercial test 1 and 2 ( Fig. S4 and S5 , ESI †).

Further to the performance evaluation of the system, 101 clinical specimens, including 44 inuenza negative, 45 inuenza A positive, 12 inuenza B positive samples, were used to evaluate the performance of the system, as described previously. No signal was detectable in all inuenza negative samples. Of those 45 inuenza A positive samples, distinct signals at TL1 and C-line positions was observed in 40 samples, matched with those tested by commercial uorescence-based rapid test. The other 5 samples revealed a weak TL1 signal, leading to a cut-off as a negative result. With this analysis, the sensitivity and specicity of the test for screening inuenza A virus were reported to be 89% and 100%, with a positive predictive value (PPV), a negative predictive value (NPV), and percent accuracy were reported to be of 100%, 90%, and 94% (Table 1 and Fig. S6, ESI †) .

With respect to inuenza B positive samples, it was reported that 10 out of 12 inuenza B positive samples showed correlated results with those obtained from commercial uorescent-based test and PCR method (molecular approach). The other two samples demonstrated weak TL2 signal, resulting in a negative result interpretation. This revealed the sensitivity and speci-city of the developed tests for screening inuenza B virus were reported to be 83% and 100%, respectively, while the PPV, NPV, and percent accuracy were reported to of 100%, 96%, and 96%, respectively (Table 1 and Fig. S6, ESI †) .

It may be also worthwhile to further discuss the differences between the developed system and other systems. Previous studies reported different technologies used in detecting inuenza virus. The most common technique used for inuenza virus screening and detection is commonly shown to be molecular based approach, in which the technique is relied upon the amplication of the virus RNA. Regarding other rapid POC technologies, the technique is oen integrated with other signal amplication technologies to enhance the sensitivity i.e. the use of gold nanoparticles, microuidic chip, and uorescent technologies. [37] [38] [39] Despite the high sensitivity, these technologies are laborious techniques and oen require highly-trained personnel and instrument during analysis and result visualization processes. Particularly, they are still time-consuming methods. With respects to these factors, lateral ow platform offers advantages in its simplicity, and rapidity, and sensitive for a rapid POC screening purposes. 

Clinical nasopharyngeal swab samples used in the evaluation were provided from Virology Unit, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand. Aer sample collection, the swabs were collected in the UTM™ transport medium (Copan Diagnostics, CA, USA). The samples were collected with full ethical approval granted by the University Ethics Committee. One hundred and one nasopharyngeal swab samples were collected from 101 patients, who had inuenza-like illness symptoms. Of these 101 samples, 45 samples were diagnosed as inuenza A virus positive, 12 samples were diagnosed as inuenza B virus positive, and 44 samples were diagnosed as both inuenza A and B virus negative using commercial uorescent rapid test and molecular approach (PCR), as reference tests. Regarding molecular approach, samples were subjected to nucleic acid extraction and amplication using MagDeA® Dx SV (Precision System Science, Chiba, Japan) and RealStar® Inuenza Screen & Type RT-PCR kit 4.0 (Altona-Diagnostics GmbH, Hamburg, Germany), respectively. Subsequent to the screening using the reference tests, the samples were immediately stored at À80 C until further use.

UV-Vis absorption spectra was recorded using a microplate reader (Power wave XS2, Bio-Tek, USA). Transmission electron microscopy (TEM) were taken on a JEM-2010 (JEOL, Japan). Surface charge of GNPs was determined by a Zetasizer (Malvern Instruments, UK). The CM4000 guillotine cutting module and the dispensing platform were obtained from BioDot (CA, USA). ESEQuant LR3 lateral ow device reader was obtained from Qiagen, Hilden, Germany.

SDS-PAGE analysis. SDS-PAGE analysis was used to separate proteins as described previously. 40 The protein samples (10 mg) were mixed with loading buffer, containing 0.625 M b-mercaptoethanol, 1.36 M glycerol, 69.4 mM SDS, 0.02 mM bromophenol blue in 62.5 mM Tris buffer (pH 6.8), before preheated at 95 C for 10 min for a preparation of electrophoresis. The proteins were separated using 15% (w/v) polyacrylamide gel with constant voltage at 100 V in a running buffer, containing 190 mM glycine and 3.48 mM SDS in 25 mM Tris buffer, pH 8.3 for 1.5 h. Aer staining and destaining, the gel was visualized and the image was record.

Western blotting analysis. Western blot analysis was performed as described previously with modication. 41 Aer electrophoresis, the proteins on the gel were transferred to a nitrocellulose membrane with constant voltage at 100 V in transfer buffer, containing 192 mM glycine and 20% (v/v) methanol in 25 mM Tris buffer (pH 8.3) for 1.5 h at RT. Aer washing and blocking step, the membrane was separately incubated with the dilution of their primary antibody, either mAb specic to inuenza A or B viruses at optimal ratio at 4 C for 16 h. Subsequently, the membrane was treated with secondary antibody (antimouse IgG, ALP conjugated) for 1 h, followed by re-rinsing step. A detection of protein bands was performed using BCIP/NBT substrate solution in the dark at RT until the color was developed. The reaction was stop by washing the membrane with distilled water and the image was recorded subsequently.

Gold nanoparticles (GNP) with the absorption maxima (A max ) at 526 nm was prepared by citrate reduction method according to a protocol described previously. 42 Briey, 100 mL of 0.01% (w/v) tetrachloroauric acid was heated to reux with continuous stirring, and 1 mL of 1% (w/v) trisodium citrate was rapidly added. The solution was boiled and stirred continuously until the color changed gradually from bright yellow to deep red. The reaction mixture was cooled and stored at 4 C.

The preparation of GNP-mAb conjugates was performed by using passive adsorption method and can be described in the following procedures. Briey, the stock suspension of spherical GNP was homogenized in sonication bath before diluted to different folds with ultrapure water. Determination of the optimal conditions was achieved using the method, as described previously. 43 The mAb was conjugated to GNP to produce 'the detector probe'. For large scale conjugate production, the procedure was described as follows: briey, a desired amount of mAb was mixed gently with 1 mL of GNP solution (optical density, O.D., at 542 nm (A max ) ¼ 1.0). Under continuous gentle mixing, the mixture was le to react for 30 min at RT, followed by the addition of 10% (w/v) BSA in 20 mM borate buffer, pH 9. Aer incubation, the conjugates were then collected by centrifugation at 4400 Â g at 4 C for 5 min before resuspending in 1% (w/v) BSA, in 20 mM borate buffer, pH 9. The nal conjugates were then stored at 4 C until used. In addition to TEM and DLS analysis, further characterization of the particles before and aer conjugation was performed using induce particle aggregation method. 43, 44 Fabrication and assembly of the lateral ow device Fabrication and the assembly of all the components of the lateral ow device can be illustrated as shown in Fig. 1 . The device consists of four main components including sample application pad, conjugate reservoir pad, reacting nitrocellulose membrane, and absorbent pad, which are assembled together in a plastic housing cassette. To prepare the reacting membrane, mAb used a capture antibody and secondary antimouse antibody in a desired amount were dispensed onto the reacting membrane to form the test-and control lines, respectively, with a distance of 5 mm from each other. With multiplexed lateral ow device, the mAb specic to the inuenza A proteins and the mAb specic to the inuenza B proteins were dispensed with a distance of 5 mm from each other and were designated as TL1 and TL2, respectively. For conjugate reservoir pad preparation, a desired volume of the conjugates was loaded on the conjugate reservoir pad. For lateral ow device assembly, all components were assembly in a manner as depicted in Fig. 1 , with the overlapping between each component of 2 mm.

Performance evaluation of the system and assay procedures Qualitative analysis method using direct signal visualization. To evaluate the system performance for the detection of the inuenza A and B viruses, the serial two-fold dilutions of sample were prepared in a following procedure: the stock solution of the protein solution was prepared using 50 mM Tris-HCl buffer, pH 9 before diluted to different concentrations ranged from 0-3000 ng per test and 0-88 mg per test, for inuenza A and B proteins, respectively. To perform the evaluation, the volume of 10 mL of each dilution was applied to the sample application window of the cassette, followed by an addition of 100 mL of the buffer containing 50 mM Tris-HCl buffer, pH 9. The reaction was allowed to react for 5 min before the signal at the T-and C-lines was visualized and recorded. The presence of both T-and C-line signal indicated the presence of the inuenza proteins in the sample, while the presence of only C-line signal indicated the negative inuenza protein detection. The performance evaluation of each dilution was performed in triplicate.

Semi-quantitative analysis using lateral ow device reader. Semi-quantitative analysis was performed using lateral ow device reader. Aer a direct signal visualization and image record, the test strip was inserted into a strip holder of the reader. The average value of the signal response, expressed as a peak height, at the T-line position (T av ) was determined and recorded at 10 min. The relative signal response (RSR) was calculated using the T av value obtained from the sample containing the target inuenza protein at various protein concentrations, compared with that obtained from the positive control (P av ). The RSR value calculation is demonstrated in the equation below. Each concentrations were obtained from three separate experiments. Either inuenza A or B proteins at the concentration of 300 ng per test and 8750 ng per test was used as positive control in each case.

The specicity of the system was evaluated by using other respiratory virus proteins including either inuenza A, inuenza B, other respiratory viruses i.e., RSV, parainuenza, and adenovirus virus, and other non-related proteins i.e., avidin, creactive protein, haemoglobin protein, and insulin proteins as samples. Assay procedure and the evaluation of specicity were performed in the same manner as described above.

To evaluate the performance of the test system, nasopharyngeal swabs were used as the clinical specimens for evaluation. A total of 101 nasopharyngeal swabs, including 44 inuenza virus negative samples, 45 inuenza A virus positive samples, and 12 inuenza B virus positive samples, were used as samples, as described previously. Prior to the sample application, the sample was mixed with an analysis buffer in a ratio of 1 : 1. Subsequently, a volume of 100 mL of the mixed sample was applied onto a sample application window of the device cassette and allowed to process before the signal was visualized directly at 5 min. The performance of the system was correlated to other methods including commercial rapid antigen detection test and molecular approach (Fig. S7, ESI †) .

Pre-clinical evaluation of the test system performance was performed and correlated to those results obtained from commercial uorescent-based test and molecular approach. To obtain sensitivity, specicity, positive and negative predictive values, and accuracy, true positive (TP), false negative (FN), true negative (TN), and false positive (FP) were used in the calculation as described previously 45, 46 (Fig. S7 , ESI †).

In summary, a visual colorimetric rapid screening system based on lateral ow device for inuenza A and B virus detection and differentiation using nucleoprotein as target molecules has been designed and developed as a model. Under optimal condition, the system is capable to detect the target molecules at ng per test level, with a detection limit of 0.04 and 1 ng per test for inuenza A and B proteins, respectively. With the integration of a reader, it is shown that the results obtained from visual colorimetric method and the semi-quantitative analysis are in good alignment. The system also showed selectivity for its target proteins against other closely related respiratory virus proteins and other non-related proteins. The performance of the system is shown to be 4-to 8-fold higher sensitive than commercial tests, using colorimetric detection. With correlation to reference methods based on commercial uorescencebased test and molecular approach, the specicity of 100% and the sensitivity of 89% and 83% for inuenza A and B viruses, respectively were demonstrated. The potential advantages of such visual colorimetric rapid screening system based on lateral ow device can be of great importance for other screening applications, including a detection and differentiation for other related infectious agents, toxins, and other contaminants. 

There are no conicts to declare.

Molecular Testing for Respiratory Viruses

pdf; jsessionid¼12044AD8127B58A34181F086DC1158B3? sequence¼1

regulatory-information/search-fda-guidance-documents/ statistical-guidance-reporting-results-studies-evaluatingdiagnostic-tests-guidance-industry-and-fda

This work was supported by grant (P1750146) from NANOTEC, Thailand.